Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Gynecologic Oncology
•
Ovarian Cancer
What is your preferred approach to adjuvant treatment for stage IC grade 1 endometrioid ovarian adenocarcinoma?
Answer from: at Community Practice
Carbo/taxol x 6 Genetics
Sign in or Register to read more
12838
Related Questions
Do you recommend bevacizumab with front-line platinum-based adjuvant chemotherapy for fully resected stage III ovarian clear cell carcinoma?
In a patient with an HR-proficient stage III high-grade serous ovarian cancer s/p R0 primary debulking surgery for whom you are not considering bevacizumab in addition to chemotherapy, would you consider IP chemotherapy?
How do you factor a decreasing but persistently elevated CA-125 into your decision regarding whether to proceed with interval cytoreductive surgery for PAX8+ high-grade serous cancer s/p neoadjuvant chemotherapy with minimal disease on imaging?
Would you hold a PARP inhibitor in the perioperative period for an ileostomy reversal in a patient who has completed primary debulking surgery followed by chemotherapy?
How do you incorporate a KELIM score into your management of patients with ovarian cancer?
How do you manage patients with germline BRCA mutations who have STIC lesions found at time of risk-reducing BSO?
Would you favor giving mirvetuximab before paclitaxel/bevacizumab?
How would you manage a patient with an incidental finding of 1 mm focus of high-grade serous carcinoma in the fallopian tube after TAHBSO was done for a benign broad ligament fibroid with negative pelvic washings?
Would you ever re-treat recurrent ovarian cancer with mirvetuximab soravtansine if the patient responded to it in the past (e.g., more than 6 months ago)?
Would you recommend surgery or stereotactic radiation therapy for a young woman with high-grade serous ovarian cancer presenting with a pelvic LN oligometastasis following maintenance therapy?